» Articles » PMID: 1679356

Enzymic Control of the Expression of the X Determinant (CD15) in Human Myeloid Cells During Maturation: the Regulatory Role of 6-sialytransferase

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1991 Sep 15
PMID 1679356
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

To establish the basis for the reduced expression of the X determinant on leukemic blasts and the changes in antigenic expression that occur during myeloid maturation, the presence on myeloid cells of X and related structures was examined in conjunction with studies on the activities of the glycosyltransferases involved in their biosynthesis. Expression of X and sialyl-X was weak on blasts in comparison with neutrophils despite the presence of the requisite precursor structures. Much higher levels of 3-fucosyltransferase activity were found in blasts than in neutrophils when nonsialylated substrates were used, but, whereas the enzyme in neutrophils reacted equally well with 3'-sialylated and nonsialylated acceptors, the enzyme in blasts showed a marked preference for nonsialylated substrates. 6'-Sialyltransferase activity was strong in blasts but was not detectable in neutrophils, whereas a much lower level of 3'-sialyltransferase activity was present in both blasts and neutrophils. Dimethyl sulfoxide-induced maturation of HL60 cells was associated with (1) a decrease in both 6'-sialyltransferase and 3-fucosyltransferase activities, (2) a change in the substrate specificity of 3-fucosyltransferase towards that found in mature cells, and (3) increased cell surface expression of sialyl-X. These results suggest that the reduced expression of X in myeloblasts is related to the presence of the strong 6'-sialyltransferase, which uses the precursor substrate at the expense of the 3-fucosyltransferase and prevents the synthesis of X and sialyl-X. The developmental regulation of the levels of 3'- and 6'-sialyltransferases, and the level and specificity of the 3-fucosyltransferases, therefore controls the expression of X and its degree of sialylation.

Citing Articles

CD15 Is a Risk Predictor and a Novel Target in Clear Cell Renal Cell Carcinoma.

Stenzel P, Schindeldecker M, Seidmann L, Herpel E, Hohenfellner M, Hatiboglu G Pathobiology. 2023; 91(3):219-229.

PMID: 37963432 PMC: 11151972. DOI: 10.1159/000535201.


Transcription of human β-galactoside α2,6-sialyltransferase (hST6Gal I) is downregulated by curcumin through AMPK signaling in human colon carcinoma HCT116 cells.

An S, Kim K, Lee Y, Kim S Genes Genomics. 2023; 45(7):901-909.

PMID: 37231294 DOI: 10.1007/s13258-023-01398-2.


High-Mannose -Glycans as Malignant Progression Markers in Early-Stage Colorectal Cancer.

Boyaval F, Dalebout H, Van Zeijl R, Wang W, Farina-Sarasqueta A, Lageveen-Kammeijer G Cancers (Basel). 2022; 14(6).

PMID: 35326703 PMC: 8945895. DOI: 10.3390/cancers14061552.


Regulation of ST6GAL1 sialyltransferase expression in cancer cells.

Dorsett K, Marciel M, Hwang J, Ankenbauer K, Bhalerao N, Bellis S Glycobiology. 2020; 31(5):530-539.

PMID: 33320246 PMC: 8176773. DOI: 10.1093/glycob/cwaa110.


Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.

Rodrigues E, Macauley M Cancers (Basel). 2018; 10(6).

PMID: 29912148 PMC: 6025361. DOI: 10.3390/cancers10060207.